Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Mainz Biomed NV (MYNZ : NSDQ)

• Company Description    Mainz Biomed N.V. develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. Mainz Biomed N.V. is based in BERKELEY, Calif. Number of Employees: 26

• Price / Volume Information    Yesterday's Closing Price: $1.49 Daily Weekly Monthly 20 Day Moving Average: 486,902 shares Shares Outstanding: 5.41 (millions) Market Capitalization: $8.07 (millions) Beta: 0.25 52 Week High: $14.39 52 Week Low: $1.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.70% -10.13% 12 Week -25.13% -28.50% Year To Date -65.51% -71.04%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ROBERT KOCH STRASSE 50 - MAINZ,2M 55129 DEU ph: 49-6131-554-2860 fax: - ir@mainzbiomed.com https://mainzbiomed.com

• General Corporate Information    Officers Guido Baechler - Chief Executive Officer William Caragol - Chief Financial Officer Heiner Dreismann - Director Chris von Toerne - Director Hans Hekland - Director Peer Information Mainz Biomed NV (CORR.) Mainz Biomed NV (RSPI) Mainz Biomed NV (CGXP) Mainz Biomed NV (BGEN) Mainz Biomed NV (GTBP) Mainz Biomed NV (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N5436L119 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 5.41 Most Recent Split Date: 12.00 (0.03:1) Beta: 0.25 Market Capitalization: $8.07 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.70 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - - 03/31/25 - - Current Ratio 09/30/25 - - 06/30/25 - 0.52 03/31/25 - - Quick Ratio 09/30/25 - - 06/30/25 - 0.43 03/31/25 - - Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 0.55 03/31/25 - - Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.44 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - 30.37 03/31/25 - -

Powered by Zacks Investment Research ©